odevixibat

BOSTON, 30 nov. 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq : ALBO), une société spécialisée dans les maladies rares qui développe de nouveaux modulateurs d'acides biliaires…

WASHINGTON -- Treatment with odevixibat (Bylvay) led to early, rapid, and sustained improvements in pruritus among…

– Oral late breaker with new results from positive Phase 3 ASSERT study in Alagille syndrome (ALGS) – Oral late breaker provides evidence of disease modification in PFIC –…

Amélioration statistiquement significative du critère d'évaluation primaire du prurit (p = 0,002).Réductions significatives du critère d'évaluation secondaire des niveaux d'acides biliaires…

Hochgradige statistisch signifikante Linderung von Juckreiz, dem primären Endpunkt (p=0,002)Signifikante Verringerung des Gallensäurespiegels im Serum, dem wichtigsten sekundären Endpunkt…

Miglioramento statisticamente molto significativo dell'endpoint primario del prurito (p=0,002)Significative riduzioni dell'endpoint chiave secondario dei livelli di acidi biliari nel siero…

Mejoría estadísticamente muy significativa en el criterio de valoración principal «prurito» (p = 0,002)Reducciones significativas en el criterio de valoración secundario clave «niveles de…

Highly statistically significant improvement in pruritus primary endpoint (p=0.002)Significant reductions in key secondary endpoint of serum bile acid levels (p=0.001)Substantial…

Positive Agenzia Italiana del Farmaco (AIFA) decision provides reimbursed access to the first medicine available for the treatment of all types of PFIC, a rare and devastating disorder that…

Odevixibat (Bylvay) reduced intense itching and serum bile acids in children with progressive…